Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BUB1 | O43683 | 5/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | ILK | Q13418 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11895090 | 0.87 | NPSR1 (0.37) | CYP1A2METAP2AAK1ILKS1PR1 | |
| SCHEMBL1665867 | 0.85 | CYP1A2 (0.46) | CYP1A2METAP2AAK1GPBAR1HPGD | |
| SCHEMBL11953201 | 0.85 | CYP17A1 (0.38) | BUB1CYP17A1 | |
| SCHEMBL11894648 | 0.79 | CYP1A2 (0.41) | CYP1A2METAP2AAK1ILKS1PR1 | |
| SCHEMBL11895093 | 0.78 | RAB9A (0.39) | CYP1A2ILKHPGD | |
| SCHEMBL1026375 | 0.77 | SGMS2 (0.34) | BUB1CYP1A2METAP2CYP17A1S1PR1 | |
| SCHEMBL11895332 | 0.77 | POLB (0.33) | CYP1A2METAP2ILKS1PR1GPBAR1 | |
| SCHEMBL117897 | 0.76 | POLB (0.42) | BUB1CYP1A2METAP2CYP17A1 | |
| SCHEMBL11894951 | 0.76 | ILK (0.34) | CYP1A2METAP2CYP17A1ILKS1PR1 | |
| SCHEMBL16612971 | 0.75 | SLC22A12 (0.33) | ILKS1PR1GPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2486035-B1 | HETEROCYCLIC COMPOUND AND ITS USE FOR CONTROL OF AN ARTHROPOD PEST | SUMITOMO CHEMICAL CO (JP) | 2015-08-26 | — | — | EP | disclosed |
| US-8742112-B2 | Heterocyclic compound and its use for control of an arthropod pest | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-06-03 | — | — | US | disclosed |
| US-8742112-B2 | Heterocyclic compound and its use for control of an arthropod pest | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-06-03 | — | — | US | disclosed |
| EP-2486035-A1 | HETEROCYCLIC COMPOUND AND ITS USE FOR CONTROL OF AN ARTHROPOD PEST | Sumitomo Chemical Co., Ltd (JP) | 2012-08-15 | — | — | EP | disclosed |
| US-20120196891-A1 | HETEROCYCLIC COMPOUND AND ITS USE FOR CONTROL OF AN ARTHROPOD PEST | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-08-02 | — | — | US | disclosed |
| US-20120196891-A1 | HETEROCYCLIC COMPOUND AND ITS USE FOR CONTROL OF AN ARTHROPOD PEST | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-08-02 | — | — | US | disclosed |
| WO-2011043404-A1 | HETEROCYCLIC COMPOUND AND ITS USE FOR CONTROL OF AN ARTHROPOD PEST | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011043404-A1 | HETEROCYCLIC COMPOUND AND ITS USE FOR CONTROL OF AN ARTHROPOD PEST | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196891-A1 | HETEROCYCLIC COMPOUND AND ITS USE FOR CONTROL OF AN ARTHROPOD PEST | HAAO, DDT, ACHE | BUB1 3350/4885CYP1A2 7/4885METAP2 3749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.